<SEC-DOCUMENT>0001193125-18-329463.txt : 20181119
<SEC-HEADER>0001193125-18-329463.hdr.sgml : 20181119
<ACCEPTANCE-DATETIME>20181119073105
ACCESSION NUMBER:		0001193125-18-329463
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20181116
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181119
DATE AS OF CHANGE:		20181119

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MYRIAD GENETICS INC
		CENTRAL INDEX KEY:			0000899923
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				870494517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26642
		FILM NUMBER:		181191227

	BUSINESS ADDRESS:	
		STREET 1:		320 WAKARA WAY
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84108
		BUSINESS PHONE:		801-584-3600

	MAIL ADDRESS:	
		STREET 1:		320 WAKARA WAY
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84108
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d657091d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): November&nbsp;16, 2018 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>MYRIAD GENETICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">0-26642</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">87-0494517</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>320 Wakara Way </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Salt Lake City, Utah 84108 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (801) <FONT STYLE="white-space:nowrap">584-3600</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
name or former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see </I>General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&nbsp;230.405 of this
chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;&nbsp;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;1.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Entry into a Material Definitive Agreement </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;16, 2018, Myriad Genetics, Inc. (the Company) entered into an accelerated share repurchase agreement (the &#147;ASR
Agreement&#148;) with Bank of America, to repurchase approximately $50&nbsp;million of the Company&#146;s common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the ASR
Agreement, Bank of America will deliver to the Company, on November&nbsp;19, 2018, shares of the Company&#146;s common stock equal to the aggregate purchase price of $50&nbsp;million divided by the Company&#146;s volume-weighted average price of
trading on November&nbsp;16, 2018. The initial number of shares of common stock will be adjusted based on a discount to the volume-weighted average share price of the common stock over a measurement period, the exact termination date of which will
be selected by Bank of America. After the termination of this period, the Company may receive additional shares of common stock or be required to remit, at the Company&#146;s election, cash or additional shares of common stock based on this average
price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the ASR Agreement is a summary and is qualified in its entirety by the terms of the ASR Agreement, a
copy of which will be filed as an exhibit to the Company&#146;s Quarterly Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> for its second fiscal quarter ending December&nbsp;31, 2018. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d657091dex991.htm">Press release dated November<U></U>&nbsp;19, 2018 announcing the Company entering into an accelerated share repurchase program. </A></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exhibit(s) may contain hypertext links to information on our website or other parties&#146; websites. The
information on our website and other parties&#146; websites is not incorporated by reference into this Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> and does not constitute a part of this
<FONT STYLE="white-space:nowrap">Form&nbsp;8-K.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>MYRIAD GENETICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date: November&nbsp;19, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ R. Bryan Riggsbee</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">R. Bryan Riggsbee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Executive Vice President, Chief Financial Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d657091dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">


<IMG SRC="g657091new1.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>News Release</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Media&nbsp;Contact:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ron Rogers</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Investor Contact:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Scott Gleason</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(801) <FONT STYLE="white-space:nowrap">584-3065</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(801) <FONT STYLE="white-space:nowrap">584-1143</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><U>rrogers@myriad.com</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><U>sgleason@myriad.com</U></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Myriad Announces $50 Million Accelerated Share Repurchase Program </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SALT LAKE CITY, Nov. 19, 2018 &#150;</B> Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that the company
has entered into an accelerated share repurchase (&#147;ASR&#148;) agreement with Bank of America, N.A. under which the company will repurchase approximately $50&nbsp;million of its common stock. Myriad currently has approximately $161&nbsp;million
remaining on its existing share repurchase authorization which has been approved by the company&#146;s board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;We
remain highly confident in the future growth prospects for the company and believe repurchasing shares at current levels will generate a very attractive return on invested capital,&#148; said R. Bryan Riggsbee, chief financial officer, Myriad
Genetics. &#147;Given our strong balance sheet, we continue to be flexible in our capital deployment, and while we prioritize strategic acquisitions, we will opportunistically consider share repurchases if stock valuation is inconsistent with
long-term fundamentals.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the ASR program, Myriad will pay an aggregate of approximately $50&nbsp;million to Bank of America,
N.A. to repurchase a number of shares that will be based on a discount to the volume-weighted average share price of its common stock over the course of a valuation period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Myriad Genetics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Myriad Genetics
Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics.&nbsp;Myriad discovers and commercializes molecular diagnostic tests that: determine the
risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower
healthcare costs.&nbsp;Myriad is focused on five strategic imperatives:&nbsp;build upon a solid hereditary cancer foundation, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit revenue internationally
and improving profitability with Elevate 2020.&nbsp;For more information on how Myriad is making a difference, please visit the Company&#146;s website: <U>www.myriad.com. </U>Follow Myriad on Twitter via @MyriadGenetics. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Myriad, the Myriad logo, BART, BRAC<I>Analysis</I>, Colaris, Colaris AP, myPath, myRisk,
Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore, Prolaris, ForeSight and Prelude are trademarks or registered trademarks of Myriad Genetics,
Inc. or its wholly owned subsidiaries in the United States and foreign countries. <FONT STYLE="white-space:nowrap">MYGN-F,</FONT> <FONT STYLE="white-space:nowrap">MYGN-G.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safe Harbor Statement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This press release
contains &#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the commencement and completion of the repurchase of an additional&nbsp;$50
million&nbsp;shares of the Company&#146;s common stock through an accelerated share repurchase (ASR) program; the purchase price of the shares acquired pursuant to the ASR agreement; the timing and duration of the ASR program; the number of shares
that will be repurchased being based on a discount to the average volume-weighted average share price of the Company&#146;s common stock over the course of a valuation period; the future growth prospects of the Company; the Company&#146;s belief
that repurchasing shares at current levels will generate a very attractive return on invested capital; the Company&#146;s flexibility in its capital deployment; the Company&#146;s prioritization of strategic acquisitions; the Company
opportunistically considering additional share repurchases if the Company perceives its stock valuation to be inconsistent with long-term fundamentals; and the Company&#146;s strategic directives under the caption &#147;About Myriad Genetics.&#148;
These &#147;forward-looking statements&#148; are based on management&#146;s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those
described or implied in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not
continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests; risks related to changes in the governmental or private insurers&#146; reimbursement levels for our tests or
our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve
commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and
clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks
related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United
States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on
satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire, including but not limited to our acquisition of Assurex, Crescendo, Sividon and
Counsyl; risks related to our projections about the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the
risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in
the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States
and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other
factors discussed under the heading &#147;Risk Factors&#148; contained in Item&nbsp;1A of our most recent Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K,</FONT> which has been filed with the Securities and Exchange Commission, as
well as any updates to those risk factors filed from time to time in our Quarterly Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> or Current Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g657091new1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g657091new1.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
MGJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H
M4JC$J3>IJ:H<JH^K JMUJ^FL7*S0K42MN*XMKJ&O%J^+L "P=;#JL6"QUK)+
MLL*S.+.NM"6TG+43M8JV ;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]
M%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_
MR#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'3
M1-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N W 7<BMT0W9;>'-ZB
MWRG?K^ VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJ
MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[
M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____VP!#  (" @(" 0("
M @(# @(# P8$ P,# P<%!00&" <)" @'" @)"@T+"0H,"@@("P\+# T.#@\.
M"0L0$1 .$0T.#@[_VP!# 0(# P,# P<$! <."0@)#@X.#@X.#@X.#@X.#@X.
M#@X.#@X.#@X.#@X.#@X.#@X.#@X.#@X.#@X.#@X.#@X.#@[_P  1" !; -X#
M 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+_\0
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M0V0-OI517,[$MV5S] 0<TM4=/CFBTV*.>3S)E0"1AT8]S5ZI*"BBB@ HHHH
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+VG44 ,I]%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
